How are energy investors positioned?
JUPITER, FL - Jupiter Neurosciences, Inc. (NASDAQ:JUNS) announced Thursday it has regained compliance with Nasdaq’s minimum share price requirement, according to a statement based on a company press release. The stock, currently trading at $1.91, has shown strong momentum with significant gains over the past three months, according to InvestingPro data.
The clinical-stage pharmaceutical company received confirmation from Nasdaq’s Listing Qualifications Department that as of July 3, 2025, its common stock maintained an average closing share price of at least $1.00 for 13 consecutive trading days from June 18 to July 8, 2025.
The company is no longer considered below the minimum bid price requirement under Rule 5550(a)(2), and Nasdaq now considers the matter closed, according to the announcement.
Jupiter Neurosciences, which develops a resveratrol-based platform called JOTROL, disclosed this update in a Current Report on Form 8-K filed with regulators on July 10.
The company pursues a dual-path strategy focused on neuroinflammation and healthy aging, with a therapeutic pipeline targeting central nervous system disorders and rare diseases. Jupiter is currently conducting a Phase IIa trial in Parkinson’s disease and exploring other indications including Alzheimer’s Disease and Friedreich’s Ataxia.
In addition to its pharmaceutical development efforts, the company markets a consumer product line called Nugevia.
In other recent news, Jupiter Neurosciences has announced several significant developments. The company approved a bonus package for its key executives, which includes stock options and cash payments contingent on available cash exceeding $3.5 million. Chief Business Officer Alison Silva and Chief Financial Officer Saleem Elmassri received stock options as part of this package. Additionally, Jupiter Neurosciences is set to launch two new supplements, Nugevia PWR and Nugevia GLO, in Fall 2025. These products aim to enhance mitochondrial health and skin health, respectively, using the company’s proprietary JOTROL technology. The Nugevia line is expected to contribute to the company’s revenue and support its clinical development programs. In another development, the company appointed Cherry Bekaert LLP as its new auditor after the resignation of Assurance Dimensions, LLC, due to their decision to cease PCAOB registrants practice. Assurance Dimensions’ previous audit reports did not contain any adverse opinions, although they noted uncertainty regarding Jupiter Neurosciences’ ability to continue as a going concern. These announcements highlight Jupiter Neurosciences’ ongoing initiatives in both consumer wellness and pharmaceutical development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.